Citius Pharma Files 8-K on 'Other Events' & Financial Exhibits
Ticker: CTXR · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1506251
Complexity: simple
Sentiment: neutral
Topics: corporate-update, regulatory-filing
TL;DR
**CTXR filed an 8-K for 'Other Events' and exhibits, signaling new disclosures.**
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits.' This filing indicates that the company is providing updated information, potentially related to its financial status or operational activities, which could impact its common stock (CTXR) traded on The Nasdaq Capital Market. For investors, this matters because any new disclosures, especially concerning financial health or strategic events, can directly influence the stock's valuation and future prospects.
Why It Matters
This filing signals that Citius Pharmaceuticals is disclosing new information that could be important for investors to understand the company's current situation and future outlook.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the undisclosed 'Other Events' could carry significant risk or opportunity, making the overall situation medium risk until details are known.
Analyst Insight
A smart investor would monitor Citius Pharmaceuticals' subsequent filings or press releases for specific details regarding the 'Other Events' and 'Financial Statements and Exhibits' to understand their impact on the company's operations and financial health.
Key Numbers
- 001-38174 — Commission File Number (Identifies Citius Pharmaceuticals, Inc. with the SEC.)
- 2024-01-23 — Date of Report (Indicates the earliest event reported in this 8-K filing.)
- 14 — Public Document Count (Number of documents included in the filing.)
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Capital Market (company) — the exchange where CTXR common stock is registered
- January 23, 2024 (date) — date of earliest event reported and filing date
- 001-38174 (dollar_amount) — Commission File Number for Citius Pharmaceuticals, Inc.
- 27-3425913 (dollar_amount) — IRS Employer Identification No. for Citius Pharmaceuticals, Inc.
Forward-Looking Statements
- Citius Pharmaceuticals will release more detailed information regarding the 'Other Events' mentioned in this 8-K. (Citius Pharmaceuticals, Inc.) — high confidence, target: 2024-02-23
FAQ
What is the primary purpose of Citius Pharmaceuticals, Inc.'s 8-K filing on January 23, 2024?
The primary purpose of Citius Pharmaceuticals, Inc.'s 8-K filing on January 23, 2024, is to report 'Other Events' and 'Financial Statements and Exhibits' as per Item 8.01 and Item 9.01, respectively.
On which stock exchange is Citius Pharmaceuticals, Inc.'s common stock traded?
Citius Pharmaceuticals, Inc.'s common stock, with a $0.001 par value and trading symbol CTXR, is registered on The Nasdaq Capital Market.
What is the business address of Citius Pharmaceuticals, Inc. as stated in the filing?
The business address of Citius Pharmaceuticals, Inc. is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016, with a telephone number of (908) 967-6677.
What is the Central Index Key (CIK) for Citius Pharmaceuticals, Inc.?
The Central Index Key (CIK) for Citius Pharmaceuticals, Inc. is 0001506251.
What was the former name of Citius Pharmaceuticals, Inc. and when did the name change occur?
Citius Pharmaceuticals, Inc. had two former names: TrailOne, Inc. (changed on 20101119) and Trail One, Inc. (changed on 20110314).
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-01-23 16:05:27
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea192042-8k_citius.htm (8-K) — 29KB
- ea192042ex99-1_citius.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001213900-24-005727.txt ( ) — 237KB
- ctxr-20240123.xsd (EX-101.SCH) — 3KB
- ctxr-20240123_lab.xml (EX-101.LAB) — 33KB
- ctxr-20240123_pre.xml (EX-101.PRE) — 22KB
- ea192042-8k_citius_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 23, 2024, we issued a press release announcing the nomination of pharmaceutical executive, Robert J. Smith, to our Board of Directors. The nomination of Mr. Smith is subject to shareholder approval at the annual meeting to be held on March 12, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01 Financial Statements and
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit Description 99.1 Press Release, dated January 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: January 23, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2